Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 84

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 84
---
       
 Nano-mupirocin (50 mg/kg) vs. free mupirocin administered prophylactically and 3 and 24 h 
 after the bacterial challenge. (B) A prophylactic dose response study. (C) Nano-mupirocin 
 administration after the bacterial challenge vs. free mupirocin administration. Survival  
 of mice in response to increasing doses of Nano-Mupirocin.                                |

Figure 7. Appearance of a typical Nano-mupirocin-treated mouse (A) vs. an untreated one (B) 24 h after bacterial challenge.

(Hair was removed prior to injection of bacteria.)

| Figure 8: Plasma profile of mupirocin                                                                                      
 after IV administration of 40 mg/kg free vs. Nano-mupirocin.                                                               
 Reference: Ahuva Cern, Ayelet Michael-Gayego,                                                                              
 Yaelle Bavli, Erez Korena, Amiram Goldblum, Allon E. Moses, Yan Q. Xiong and Yechezkel Barenholz* Nano-mupirocin: enabling 
 the parenteral activity of mupirocin DOI 10.1515/ejnm-2016-0006                                                            |

<div align='center'>51</div>

| 5. | Biodistribution      
 and Pharmacokinetics |

PK studies in mice (n=4 per time point) showed
that Nano-Mupirocin had a terminal half-life of 262 minutes vs. 5.3 minutes for free mupirocin. The area under the curve (AUC) was ~97-fold
higher for Nano-Mupirocin, confirming sustained systemic exposure. Biodistribution studies showed accumulation in infected organs and
in mucosal secretions (e.g., vaginal fluid), maintaining drug concentrations well above the MIC₉₀ for >24h

| Figure                                                                                      
 9: Vaginal Smear Fluorescence. Fluorescence microscopy of vaginal smears. (A,B) are         
 overlays of Differential interference contrast (DIC) and                                    
 Fluorescent Light. (A), un-treated mice; (B), mice treated with LRPE-Nano-mupirocin; (C,D), 
 smears of LRPE-Nano-mupirocin observed under fluorescent light. Scale bar = 50 μm.          |

Figure 10: Mupirocin in Vaginal Secretions. Mupirocin concentration (free (non-liposomal)